// App-Quantinova.ai

e20067 : Genome-wide screen of DNA methylation study in stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment.

Researchers

Presenter

  • Xiaomin Niu

Principal Investigators

  • Fatao Liu

  • Yi Zhou

  • Daizhan Zhou

  • Ziming Li

  • Xiangyun Ye

  • Yongfeng Yu

  • Yun Liu

  • Zhiwei Chen

  • Shun Lu

Medical Centers

  • Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai 200030, PR China, Shanghai, China

  • Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

  • Shanghai Chest Hospital Shanghai Lung Cancer Clinical Medical Center, Shanghai, China

  • Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

  • Institutes of Biomedical Sciences, Fudan University, Shanghai, China

  • Shanghai Renji Hospital, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

Biomarkers

  • DNA methylation

Drug/Treatment

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved